India · Delayed Price · Currency is INR Biocon Statistics
Total Valuation
Biocon has a market cap or net worth of INR 516.69 billion. The enterprise value is 715.34 billion.
| Market Cap | 516.69B |
| Enterprise Value | 715.34B |
Important Dates
The next estimated earnings date is Wednesday, July 30, 2025.
| Earnings Date | Jul 30, 2025 |
| Ex-Dividend Date | Jul 4, 2025 |
Share Statistics
Biocon has 1.33 billion shares outstanding. The number of shares has increased by 0.11% in one year.
| Current Share Class | 1.33B |
| Shares Outstanding | 1.33B |
| Shares Change (YoY) | +0.11% |
| Shares Change (QoQ) | +0.43% |
| Owned by Insiders (%) | 56.00% |
| Owned by Institutions (%) | 20.76% |
| Float | 583.07M |
Valuation Ratios
The trailing PE ratio is 45.77 and the forward PE ratio is 60.33. Biocon's PEG ratio is 1.52.
| PE Ratio | 45.77 |
| Forward PE | 60.33 |
| PS Ratio | 3.39 |
| PB Ratio | 1.86 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 26.85 |
| P/OCF Ratio | 12.72 |
| PEG Ratio | 1.52 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 22.47, with an EV/FCF ratio of 37.17.
| EV / Earnings | 70.60 |
| EV / Sales | 4.69 |
| EV / EBITDA | 22.47 |
| EV / EBIT | 46.36 |
| EV / FCF | 37.17 |
Financial Position
The company has a current ratio of 1.14, with a Debt / Equity ratio of 0.66.
| Current Ratio | 1.14 |
| Quick Ratio | 0.71 |
| Debt / Equity | 0.66 |
| Debt / EBITDA | 5.77 |
| Debt / FCF | 9.54 |
| Interest Coverage | 1.74 |
Financial Efficiency
Return on equity (ROE) is 5.40% and return on invested capital (ROIC) is 2.20%.
| Return on Equity (ROE) | 5.40% |
| Return on Assets (ROA) | 1.68% |
| Return on Invested Capital (ROIC) | 2.20% |
| Return on Capital Employed (ROCE) | 3.47% |
| Revenue Per Employee | 9.35M |
| Profits Per Employee | 621,085 |
| Employee Count | 16,315 |
| Asset Turnover | 0.27 |
| Inventory Turnover | 1.22 |
Taxes
In the past 12 months, Biocon has paid 4.57 billion in taxes.
| Income Tax | 4.57B |
| Effective Tax Rate | 24.23% |
Stock Price Statistics
The stock price has increased by +18.38% in the last 52 weeks. The beta is 0.24, so Biocon's price volatility has been lower than the market average.
| Beta (5Y) | 0.24 |
| 52-Week Price Change | +18.38% |
| 50-Day Moving Average | 355.81 |
| 200-Day Moving Average | 348.08 |
| Relative Strength Index (RSI) | 68.34 |
| Average Volume (20 Days) | 5,518,631 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Biocon had revenue of INR 152.62 billion and earned 10.13 billion in profits. Earnings per share was 8.46.
| Revenue | 152.62B |
| Gross Profit | 92.44B |
| Operating Income | 15.43B |
| Pretax Income | 18.87B |
| Net Income | 10.13B |
| EBITDA | 31.24B |
| EBIT | 15.43B |
| Earnings Per Share (EPS) | 8.46 |
Balance Sheet
The company has 45.65 billion in cash and 183.62 billion in debt, giving a net cash position of -137.97 billion or -103.39 per share.
| Cash & Cash Equivalents | 45.65B |
| Total Debt | 183.62B |
| Net Cash | -137.97B |
| Net Cash Per Share | -103.39 |
| Equity (Book Value) | 277.13B |
| Book Value Per Share | 180.66 |
| Working Capital | 19.52B |
Cash Flow
In the last 12 months, operating cash flow was 40.61 billion and capital expenditures -21.37 billion, giving a free cash flow of 19.25 billion.
| Operating Cash Flow | 40.61B |
| Capital Expenditures | -21.37B |
| Free Cash Flow | 19.25B |
| FCF Per Share | 14.42 |
Margins
Gross margin is 60.57%, with operating and profit margins of 10.11% and 6.64%.
| Gross Margin | 60.57% |
| Operating Margin | 10.11% |
| Pretax Margin | 12.36% |
| Profit Margin | 6.64% |
| EBITDA Margin | 20.47% |
| EBIT Margin | 10.11% |
| FCF Margin | 12.61% |
Dividends & Yields
This stock pays an annual dividend of 0.50, which amounts to a dividend yield of 0.13%.
| Dividend Per Share | 0.50 |
| Dividend Yield | 0.13% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 5.92% |
| Buyback Yield | -0.11% |
| Shareholder Yield | 0.02% |
| Earnings Yield | 1.96% |
| FCF Yield | 3.72% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on June 12, 2019. It was a forward split with a ratio of 2.
| Last Split Date | Jun 12, 2019 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Biocon has an Altman Z-Score of 1.63 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.63 |
| Piotroski F-Score | 6 |